ProCE Banner Activity

CE / CME

Immuno-Oncology Combinations in Advanced RCC: Building on Recent Progress

Case Challenge
Multimedia
In this interactive on-demand Webcast, gain expert perspectives on the latest developments in immuno-oncology combinations for advanced RCC including management of disease-related complications or adverse events.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Pharmacists: 1.00 contact hour (0.1 CEUs)

Registered Nurses: 1.00 Nursing contact hour

Physician Assistants: maximum of 1.00 hour of AAPA Category I (Preapproved) credit

Released: November 04, 2020

Expiration: November 03, 2021

No longer available for credit.

Share

Provided by

Provided by National Comprehensive Cancer Network, in partnership with Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by a medical education grant from Exelixis, Inc.

Supported by an independent educational grant from Merck & Co., Inc.

Supported by educational grants from

Eisai

Pfizer, Inc.

Target Audience

This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with RCC.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the rationale for combining immune checkpoint inhibitors with another immune checkpoint inhibitor or VEGFR TKIs for the treatment of RCC
  • Identify patients most likely to benefit from immune checkpoint inhibitor–based combination therapy based on risk and biomarker assessment, along with patient medical and treatment history
  • Plan optimal first-line treatment for individual patients with advanced or metastatic RCC, taking into consideration immune checkpoint inhibitor combination options, available clinical evidence, expert recommendations, and patient preferences
  • Apply clinical evidence and expert recommendations to select optimal treatment for patients with progressive RCC after 1 or more previous lines of therapy
  • Plan therapeutic strategies that optimize the sequence of therapies to provide the best outcome to patients with RCC
  • Manage specific disease-related complications or adverse events associated with immuno-oncology combinations for advanced RCC

Staff Disclosure

Staff

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jason J. Everly, PharmD

Jason Everly, PharmD, has no relevant conflicts of interest to report.

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed that a spouse/partner has ownership interest (stock) in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Credit Designation

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 3, 2021. PAs should only claim credit commensurate with the extent of their participation.

Credit Designation

NCCN designates this application-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN - JA4008196-0000-20-105-H01-P.

Type of Activity: Application

Attention Pharmacists:
Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Disclosure of Unlabeled Use

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 04, 2020, through November 03, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with renal cell carcinoma.